ArticleNeurosurgical review2025
Primary intracranial alveolar soft part sarcomas: a report of seven cases and a pooled analysis of individual patient data.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrimary intracranial alveolar soft part sarcoma (PIASPS) represents an exceptionally rare entity. This study aims to characterize its clinical manifestations and evaluate prognostic factors affecting overall survival (OS) and progression-free survival (PFS).
methodsFrom 2012 to 2023, Beijing Tiantan Hospital diagnosed and treated 7 cases of PIASPS. Through a systematic PubMed literature review spanning 1988-2023 using the search terms 'primary intracranial alveolar soft part sarcoma,' we identified 17 additional published cases. Pooled analysis of these 24 cases was performed to evaluate prognostic factors affecting OS and PFS.
resultsOur cohort comprised 24 patients (10 males, 14 females) with a mean age of 26.0 ± 16.9 years (range: 3-72 years). With a mean follow-up of 38.2 ± 43.5 months, we observed tumor recurrence in 9 (45%) patients and mortality in 5 (22.7%) patients within 45.3 ± 39.0 months. Survival analysis revealed 1-, 2-, and 5-year OS rates of 100%, 88.5%, and 71.9%, respectively, with corresponding PFS rates of 77.4%, 58.0%, and 41.5%. Both univariate and multivariate Cox regression analyses identified non-gross total resection (Non-GTR) as a significant independent prognostic factor for worse OS (p = 0.031) and PFS (p = 0.009).
conclusionOur study demonstrates that PIASPS predominantly affects pediatric and young adult populations without significant gender predilection. Surgical intervention with gross total resection (GTR) was identified as the primary determinant of favorable outcomes, whereas adjuvant radiotherapy and chemotherapy demonstrated limited therapeutic efficacy. These preliminary findings warrant validation through larger, multicenter prospective studies to establish evidence-based management guidelines for this rare entity.
Indexed as
Identifiers
40615751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.